DES

IGF-1 DES

Muscle Growth Hormone Preclinical (animal)

Truncated IGF-1 missing first 3 amino acids. In animal and cell studies, 2-3x more potent than IGF-I for glucose lowering, attributed to weak IGFBP binding.

Regulatory status (as of Sept 2026)

Not FDA-approved. WADA-prohibited (IGF-1 analogues).

See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote
Educational summary. Every effect described below is drawn from the cited published research and describes what was observed in research subjects — not a promise of results, a dose recommendation, or an endorsement for human use. Many peptides are not FDA-approved. Consult a licensed healthcare provider before making any health decision. Full disclaimer.

3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content

TL;DR — IGF-1 DES at a Glance

IGF-1 DES is a compound studied only in animals and lab experiments so far. Truncated IGF-1 missing first 3 amino acids.

Half-lifeNot established in published research
detailsNo published PK data found (des(1-3)IGF-I clears more rapidly than IGF-I in pigs/marmosets, but no published t1/2 value was found)
How it's given in studiesIntramuscular (site-specific)
Research stagePreclinical (animal)
Dosing
Published research: No published human dosing
detailsMarmosets 42-270 µg/kg IV bolus; pigs 20-50 µg/kg IV bolus (Tomas 1997).
Community-reportedCommunity-reported: 50–150 mcg (site-specific), intramuscular (site-specific)

Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels   Lab / animalrodent, cell and ex vivo studies   Community-reporteduser experience and commonly used protocols, not from clinical studies

How It Works

In plain terms: It is a shortened form of the growth factor IGF-1 that is less held back by the proteins that normally bind IGF-1. Binds the IGF-1 receptor but binds poorly to IGF-binding proteins. In pigs and marmosets, IGF-I variants with poor IGF-binding-protein affinity, including des(1-3)IGF-I, had more potent and prolonged hypoglycaemic action than native IGF-I (Tomas 1997).

Effects Reported in Research

How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.

  • Lab / animalIn animal studies: enhanced anabolic effects

What Users Report (Community, Not Clinical)

Commonly reported protocol

Community-reportedIn user communities, IGF-1 DES is typically run at 50–150 mcg — intramuscular (site-specific). This is not a recommendation.

What users report

  • Community-reportedLocalized muscle growth
  • Community-reportedPotent fat loss

Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.

Side Effects and Safety Notes

  • Lab / animalHypoglycemia (2-3x more potent and more prolonged than IGF-I in pigs/marmosets)
  • No human safety data

References

  1. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
    Tomas FM, Walton PE, Dunshea FR, Ballard FJ. The Journal of endocrinology. 1997. PMID: 9415072.
    Study type: Pig and marmoset IV bolus.
    DOI: 10.1677/joe.0.1550377 · PubMed
  2. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells
    Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y. The Journal of biological chemistry. 1997. PMID: 9195961.
    Study type: In vitro cell lines.
    DOI: 10.1074/jbc.272.26.16514 · PubMed
  3. Effects of chronic renal failure on plasma clearance of insulin-like growth factor I, des-(1-3)IGF-I, and LR3IGF-I
    Gillespie CM, Hazel SJ, Walton PE, Martin AA. The American journal of physiology. 1996. PMID: 8897852.
    Study type: Rat clearance study.
    DOI: 10.1152/ajpendo.1996.271.4.E649 · PubMed

Get the weekly Dispatch

New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.

How IGF-1 DES Compares

PeptideHalf-LifeRouteResearch Status
IGF-1 DESNo published PK data found (des(1-3)IGF-I clears more rapidly than IGF-I in pigs/marmosets, but no published t1/2 value was found)Intramuscular (site-specific)Preclinical (animal)
ACE-031~12 daysSubcutaneous injectionDiscontinued
Follistatin 344UnknownSubcutaneous injectionPreclinical (animal)
IGF-1 LR3No published PK data foundSubcutaneous or intramuscularPreclinical (animal)
MGF (Mechano Growth Factor)No published PK data foundIntramuscular (site-specific)Preclinical (animal)

Values reflect figures reported in published research. Compare any peptides side-by-side →

Frequently Asked Questions

What is IGF-1 DES?
Truncated IGF-1 missing first 3 amino acids. In animal and cell studies, 2-3x more potent than IGF-I for glucose lowering, attributed to weak IGFBP binding.
How does IGF-1 DES work?
In plain terms: It is a shortened form of the growth factor IGF-1 that is less held back by the proteins that normally bind IGF-1. Binds the IGF-1 receptor but binds poorly to IGF-binding proteins. In pigs and marmosets, IGF-I variants with poor IGF-binding-protein affinity, including des(1-3)IGF-I, had more potent and prolonged hypoglycaemic action than native IGF-I (Tomas 1997).
What is the research status of IGF-1 DES?
IGF-1 DES is at the following stage in the published literature: Preclinical (animal). All information is for research and educational purposes only.
What is the half-life of IGF-1 DES?
Reported half-life: No published PK data found (des(1-3)IGF-I clears more rapidly than IGF-I in pigs/marmosets, but no published t1/2 value was found).
How is IGF-1 DES administered in research?
Reported administration route in the literature: Intramuscular (site-specific). This is not a recommendation for human use.

Quick Actions

Category

This peptide belongs to the Muscle category. View All Muscle Peptides

Related Categories

Growth Hormone

Related Peptides

From Our Affiliated Clinic

Prefer physician oversight? See how 1836 Wellness works.

1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.

See how it works →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Sources & Methodology

Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.

← Back to Peptide Library Dosing Calculator The Dispatch Home